logo

Cardiff Oncology Inc (CRDF) Stock: A Comprehensive 52-Week Review

Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Cardiff Oncology Inc’s current trading price is -65.11% away from its 52-week high, while its distance from the 52-week low is 138.30%. The stock’s price range during this period has varied between $0.94 and $6.42. The company, active in the Healthcare sector, saw a trading volume of around 0.54 million for the day, considerably lower average daily volume of 0.61 million observed over the last three months.

The market performance of Cardiff Oncology Inc has been somewhat stable. Over the past year, the company’s stock achieved a high of $6.42 on 03/25/24, with the lowest value for the same timeframe being $0.94, recorded on 11/10/23.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

How Financial Performance Impacts Market Capitalization

Cardiff Oncology Inc (CRDF) has experienced a quarterly decline of -35.26% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 100.17M and boasts a workforce of 32 employees.

The Role of Moving Averages and Trading Volume in Technical Analysis

Based on Barchart.com data, the company’s moving average over the 100-day period was 3.56, with a change in price of -3.16. Similarly, Cardiff Oncology Inc recorded 793,747 in trading volume during the last 100 days, posting a change of -58.52%.

How CRDF’s Debt-to-Equity Ratio Affects Financial Health

A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for CRDF stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.

CRDF Stock Stochastic Average

As of today, the raw stochastic average of Cardiff Oncology Inc over the last 50 days is at 15.44%. This shows a declinee from the raw stochastic average of the previous 20 days, which was recorded at 36.22%. Further, the company’s Stochastic %K and %D values for the last 20 days were 21.02% and 24.31%, respectively.

CRDF Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Year to date metric has recorded a gain of 51.35%.However, over the last six months, we can see a weaker performance of 50.34%. Over the last 30 days, the price of CRDF has fallen by 0.90%. And in the last five days, it has fallen by -1.75%.

Most Popular